Real-World Experience Using Tafasitamab Plus Lenalidomide and/or Loncastuximab Tesirine in a Predominately Hispanic Population with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Latiolais, Heidi [1 ]
Horowitz, Justin [1 ]
Michalek, Joel [2 ]
Duque, Adolfo Enrique Diaz [1 ]
机构：
[1] Univ Texas Hlth San Antonio, MD Anderson Canc Ctr, San Antonio, TX USA
[2] Univ Texas Hlth San Antonio, Dept Populat Hlth Sci, San Antonio, TX USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-207515
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7780 / 7781
页数：2
相关论文
共 50 条
  • [21] Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
    Atesoglu, Elif Birtas
    Gulbas, Zafer
    Uzay, Ant
    Ozcan, Muhit
    Ozkalemkas, Fahir
    Dal, Mehmet Sinan
    Kalyon, Hakan
    Akay, Olga Meltem
    Deveci, Burak
    Bekoz, Huseyin
    Sevindik, Omur Gokmen
    Toptas, Tayfur
    Yilmaz, Fergun
    Koyun, Derya
    Alkis, Nihan
    Alacacioglu, Inci
    Sonmez, Mehmet
    Yavasoglu, Irfan
    Tombak, Anil
    Mehtap, Ozgur
    Kurnaz, Fatih
    Yuce, Orhan Kemal
    Karakus, Volkan
    Turgut, Mehmet
    Kurekci, Derya Deniz
    Ayer, Mesut
    Keklik, Muzaffer
    Buyuktas, Deram
    Ozbalak, Murat
    Ferhanoglu, Burhan
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 663 - 673
  • [22] Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T- Cell Therapy in the US
    Epperla, Narendranath
    Lucero, Melanie
    Bailey, Tom
    Mirams, Laura
    Cheung, Jolenta
    Amet, Mona
    Milligan, Gary
    Keir, Chris
    Chen, Lei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S476 - S476
  • [23] Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Epperla, Narendranath
    Lucero, Melanie
    Bailey, Tom
    Mirams, Laura
    Cheung, Jolenta
    Amet, Mona
    Milligan, Gary
    Chen, Lei
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [24] New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment
    Tauveron-Jalenques, Urbain
    Bay, Jacques-Olivier
    BULLETIN DU CANCER, 2023, 110 (05) : 476 - 477
  • [25] Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
    Qualls, David A.
    Lambert, Nicholas
    Caimi, Paolo F.
    Merrill, Mwanasha
    Pullarkat, Priyanka
    Godby, Richard C.
    Bond, David A.
    Wehmeyer, Graham T.
    Romancik, Jason
    Amoozgar, Behzad
    Leslie, Lori
    Nastoupil, Loretta J.
    Crombie, Jennifer L.
    Abramson, Jeremy S.
    Khurana, Arushi
    Nowakowski, Grzegorz S.
    Maddocks, Kami
    Rutherford, Sarah C.
    Kahl, Brad
    Okwali, Michelle
    Buege, Michael J.
    Seshan, Venkatraman
    Batlevi, Connie L.
    Salles, Gilles
    BLOOD, 2023, 142 (26) : 2327 - 2331
  • [26] Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
    Saverno, Kim
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Epperla, Narendranath
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S464 - S464
  • [27] Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma
    Crombie, Jennifer L.
    Jun, Monika
    Wang, Tongsheng
    Mutebi, Alex
    Wang, Anthony
    Chhibber, Anindit
    Kamalakar, Rajesh
    Ukropec, Jon
    Blaedel, Julie
    Kalsekar, Anupama
    LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1623 - 1633
  • [28] RE-MIND: comparison of tafasitamab plus lenalidomide (L-MIND) vs lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma
    Zinzani, P. L.
    Rodgers, T.
    Marino, D.
    Frezzato, M.
    Barbui, A. M.
    Castellino, C.
    Meli, E.
    Fowler, N. H.
    Salles, G.
    Feinberg, B.
    Kurukulasuriya, N.
    Tillmanns, S.
    Parche, S.
    Dey, D.
    Fingerle-Rowson, G.
    Ambarkhane, S.
    Winderlich, M.
    Nowakowski, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 59 - 59
  • [29] Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States
    Saverno, Kimberly
    Nastoupil, Loretta
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Gentile, Danielle
    Asgarisabet, Parisa
    Epperla, Narendranath
    BLOOD, 2024, 144 : 2375 - 2376
  • [30] Positive CHMP Opinion on Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with relapsed or refractory diffuse large B-cell Lymphoma
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2021, 48 (04) : 263 - 263
12345